Compare BOKF & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOKF | DVA |
|---|---|---|
| Founded | 1910 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.2B |
| IPO Year | N/A | 1995 |
| Metric | BOKF | DVA |
|---|---|---|
| Price | $121.44 | $114.41 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $117.82 | ★ $145.00 |
| AVG Volume (30 Days) | 285.1K | ★ 767.7K |
| Earning Date | 01-16-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 15.51 | 5.63 |
| EPS | 8.40 | ★ 9.76 |
| Revenue | $2,107,957,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $7.26 | $6.50 |
| Revenue Next Year | $6.47 | $2.97 |
| P/E Ratio | $14.42 | ★ $11.75 |
| Revenue Growth | 5.14 | 5.14 |
| 52 Week Low | $85.08 | $113.97 |
| 52 Week High | $122.04 | $179.60 |
| Indicator | BOKF | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 37.76 |
| Support Level | $118.49 | $114.65 |
| Resistance Level | $122.04 | $117.44 |
| Average True Range (ATR) | 2.11 | 2.51 |
| MACD | 0.11 | -0.24 |
| Stochastic Oscillator | 91.34 | 13.59 |
BOK Financial Corp is a financial institution in Oklahoma, and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services, including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking, and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.